640 articles
Higenamine hydrochloride
Higenamine hydrochloride (盐酸去甲乌药碱), also called norcoclaurine hydrochloride, is a benzylisoquinoline β-adrenoceptor agonist from aconite, approved in China in April 2026 as the first class 1 innovative cardiac stress agent for myocardial perfusion imaging.
Histrelin
Histrelin acetate (Supprelin LA, Vantas) is a GnRH agonist nonapeptide delivered as a once-yearly subcutaneous hydrogel implant, used for central precocious puberty and advanced prostate cancer.
HRS-1596
HRS-1596 (Hengrui Pharma) is a phase 1-ready oral GLP-1R/GIPR dual agonist for once-weekly dosing in obesity and type 2 diabetes, licensed to Novo Nordisk on 29 September 2026 for up to $2.6 billion excluding Greater China.
HRS-4729
HRS-4729 (KAI-4729) is Hengrui's once-weekly injectable GLP-1/GIP/glucagon tri-agonist peptide for obesity, licensed to Kailera outside Greater China; its Phase 1 trial showed 16.0% weight loss at 12 weeks.
HRS-5346
HRS-5346 (MK-7262) is Hengrui's oral small-molecule lipoprotein(a) inhibitor, licensed to MSD outside Greater China for $200 million upfront; Phase 2 in China cut Lp(a) up to 86% at 12 weeks.
HRS-7249
HRS-7249: GalNAc-conjugated APOC3-targeting siRNA injection by Hengrui's Shanghai Tuojie unit, in phase 2 China trials for hyperlipidemia and severe hypertriglyceridemia; phase 1 TG cuts of 62-75%.
HRS-7535
HRS-7535 is Jiangsu Hengrui's once-daily oral small-molecule (nonpeptide) GLP-1 receptor agonist for type 2 diabetes and weight management; phase 2 trials showed HbA1c cuts up to 1.57% and weight loss up to 9.36%, with a China NDA accepted in 2026.
HRS9531 (瑞普泊肽)
HRS9531 (瑞普泊肽, ribupatide, KAI-9531) is Jiangsu Hengrui's once-weekly dual GLP-1/GIP receptor agonist for obesity and type 2 diabetes; phase 3 showed 19.2% weight loss at 48 weeks, with NDAs filed in China.
HS-10535
HS-10535, also known as MK-4082, is an investigational oral small-molecule GLP-1 receptor agonist for obesity developed by China's Hansoh Pharma and globally licensed to Merck & Co. in December 2024.
HS-20094
HS-20094 (olatorepatide, 奥莱泊肽) is Hansoh Pharma's once-weekly dual biased GLP-1/GIP receptor agonist for diabetes and obesity, licensed to Regeneron outside Greater China; Phase 3 showed up to 19.3% weight loss at 48 weeks.
Huzhen Qingfeng capsules
Huzhen Qingfeng capsules (虎贞清风胶囊, formerly Huzhen Tongfeng capsules) are a Class 1.1 innovative traditional Chinese medicine approved by China in 2021 for mild-to-moderate acute gouty arthritis.
Hybutimibe
Hybutimibe (海博麦布, hyzetimibe, HS-25; brand Saisimei) is an oral NPC1L1 cholesterol absorption inhibitor made by Zhejiang Hisun, approved in China June 2021 for primary hypercholesterolemia, dosed 10 or 20 mg daily, adding about 16% LDL-C reduction to statins.
Hydralazine
Hydralazine, a direct arteriolar vasodilator antihypertensive introduced in 1951, treats severe hypertension in pregnancy, resistant hypertension, and, with isosorbide dinitrate, Black patients with heart failure; key risk is drug-induced lupus.
Hydrochlorothiazide
Hydrochlorothiazide (HCTZ) is a thiazide-type diuretic inhibiting the renal NCC transporter, used for hypertension and edema; the most prescribed US thiazide (~31.8 million 2023 prescriptions), with electrolyte, metabolic, and small skin-cancer risks.
Hydroflumethiazide
Hydroflumethiazide (Saluron, Diucardin) is an oral thiazide diuretic and antihypertensive benzothiadiazine, C8H8F3N3O4S2, inhibiting the SLC12A3 sodium-chloride symporter; discontinued in the US.
Hydroxyprogesterone caproate
Hydroxyprogesterone caproate (17-OHPC; Delalutin, Makena, Proluton Depot) is a synthetic long-acting progestin ester given weekly by intramuscular injection. FDA approved it in 2011 to prevent recurrent preterm birth and withdrew that approval in April 2023; the EU suspended it in 2024.
Ibutilide
Ibutilide (ibutilide fumarate, Corvert) is an intravenous class III antiarrhythmic for acute cardioversion of atrial fibrillation and flutter, acting via I_Kr blockade and late sodium current activation, with torsades de pointes as its main risk.
Idebenone
Idebenone (Raxone) is a synthetic short-chain benzoquinone, a non-natural CoQ10 analogue developed by Takeda, acting as a mitochondrial electron carrier bypassing complex I; EU-approved for LHON, investigated in Friedreich ataxia, DMD, and Alzheimer's disease.
Idrabiotaparinux sodium
Idrabiotaparinux sodium (SSR126517E) is a biotinylated, once-weekly injectable indirect factor Xa inhibitor pentasaccharide derived from idraparinux, reversible with avidin; tested in EQUINOX, CASSIOPEA, and BOREALIS-AF but never marketed.
Idraparinux
Idraparinux (SANORG 34006, SR 34006) is a synthetic, antithrombin-dependent factor Xa inhibitor pentasaccharide, an analogue of fondaparinux, given as 2.5 mg weekly subcutaneous injections; phase III trials showed excess bleeding and development ceased.
Imidafenacin
Imidafenacin (KRP-197/ONO-8025) is a selective M3 antimuscarinic for overactive bladder, dosed 0.1 mg twice daily, 57.8% oral bioavailability, ~3 h half-life, approved in Japan.
Imidapril
Imidapril (Tanatril) is a long-acting prodrug ACE inhibitor, activated to imidaprilat in the liver, used for hypertension, renal parenchymal hypertension, type 1 diabetic nephropathy, and chronic heart failure; first approved 1993.
Imiglitazar
Imiglitazar (TAK-559) is a Takeda dual PPARα/γ agonist (glitazar) for type 2 diabetes; phase 3 development was discontinued in 2004 after liver enzyme abnormalities, and it was never approved.
IMPACTonIMT trial
IMPACTonIMT (NCT01291641) trial: randomized Korean-Chinese study of probucol, or probucol plus cilostazol, added to statins in coronary artery disease; no carotid IMT benefit at 3 years.
Inclisiran
Inclisiran (brand name Leqvio) is a small interfering RNA drug targeting PCSK9 that lowers LDL cholesterol, given by subcutaneous injection twice a year and used with statins in adults with high cholesterol.
Indecainide
Indecainide (Decabid, LY 135837) is a discontinued Eli Lilly class IC antiarrhythmic, a fluorene sodium-channel blocker approved in 1989 for ventricular tachycardia, limited by proarrhythmia in left ventricular dysfunction.
Indoramin
Indoramin (Wy-21901; Baratol, Doralese) is a selective alpha-1 adrenergic antagonist, C22H25N3O, formerly used for hypertension and benign prostatic hyperplasia; low oral bioavailability, 6-hydroxylation metabolism, sedation as main side effect.
Inotrope
Inotrope: drug altering cardiac contractility; positive inotropes (dobutamine, milrinone, levosimendan, digoxin, catecholamines) support cardiogenic shock and decompensated heart failure; no overall survival benefit, arrhythmia and hypotension risks.
Insulin (medication)
Insulin (medication): injectable pancreatic hormone used to control blood glucose in diabetes, essential in type 1 diabetes. Types span rapid-acting (15-minute onset) to ultra long-acting (36+ hours); biosimilars Merilog and Kirsty approved 2025; discovered Toronto 1921, Nobel 1923.
Insulin and noiiglutide fixed-dose combination (舒地胰岛素诺利糖肽)
舒地胰岛素诺利糖肽 (HR17031) is Hengrui's once-daily fixed-ratio injection of basal insulin sudelidec (INS068) plus the GLP-1 receptor agonist noiiglutide for type 2 diabetes; NMPA accepted its NDA in March 2026 after two positive phase 3 trials versus insulin glargine.